Although FDA has approved butalbital acetaminophen and caffeine each of these drugs individually, their combination in one product constitutes a new drug. We also are searching out niche areas with little competition or that butalbital acetaminophen and caffeine will add breadth to our rapidly growing product line. Able Laboratories (OTCBB:ABRX) is a rapidly growing developer and manufacturer of generic pharmaceuticals. The Private Securities Litigation Reform Act of 1995 provides butalbital acetaminophen and caffeine a safe harbor for forward-looking Statements. Able has recently completed its transition to focus the company's activities primarily on generic drug development, manufacturing and sales. Louis, Mo.
, contains acetaminophen, caffeine, codeine, and butalbital (a butalbital acetaminophen and caffeine barbiturate). Certain information included in this news release (as well as information included in oral statements or other written statements made or to be made by Able Laboratories, Inc. Under FDA regulations, a new drug can't be marketed until the company submits-and FDA approves-a new butalbital acetaminophen and caffeine drug application. Robert Cusick, Chairman and Chief Executive Officer butalbital acetaminophen and caffeine of Able Laboratories, Inc. Butalbital acetaminophen and caffeine in May 1988, the U. These are very exciting times for us. Butalbital acetaminophen and caffeine and Puerto Rico for the treatment of tension headache.
The company focuses on the respiratory, otic, gastrointestinal, pain and inflammation therapeutic markets. We anticipate that these recent approvals butalbital acetaminophen and caffeine will support revenue growth and bring us closer to profitability. Able Laboratories (OTCBB:ABRX) is a rapidly growing developer and manufacturer of generic pharmaceuticals. Novartis butalbital acetaminophen and caffeine also will discontinue the manufacture, distribution and sale of the pain killer Fioricet (butalbital/acetaminophen/caffine) tablets 100s (unit dose) and will discontinue the sale of angina treatment Transderm-Nitro (nitroglycerin transdermal) entirely. These areas include suppositories butalbital acetaminophen and caffeine and extended release formulations. Able's focus is to develop products that offer attractive market opportunities within selected niche markets of the generic drug industry. Darvocet-N is a registered trademark of Eli Lilly. The approval followed the FDA's Division of Bioequivalence's determination that Able's Butalbital, Acetaminophene, Caffeine Tablets USP, 50mg/500mg/40mg are bioequivalent and, therefore, therapeutically equivalent to the Esgic Plus(R) tablets of Mikart, Inc. Butalbital acetaminophen and caffeine zebutal(tm) capsule is an important entry into an under promoted market. Our research shows that physicians prefer products such as Zebutal(TM) that contain higher amounts of acetaminophen.